Finance
Pharmaceutical company reports fourth quarter results
Published in Drug Week, April 1st, 2005
POZEN reported a net loss of $8.4 million, or $0.29 per share on a fully diluted basis, for the fourth quarter of 2004, compared to a net loss of $1.6 million, or $0.06 per share on a fully diluted basis, for the fourth quarter of 2003.
Revenue for the quarters ended December 31, 2004, and December 31, 2003 totaled $2.4 and $1.8 million, respectively. Revenue resulted from the amortization of upfront payments received in 2003 pursuant to collaboration agreements for MT 100, MT 300, and Trexima, and revenue earned for conducting additional U.S. Food and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2005-04-01)
More Articles from Drug Week
- Age-Related Macular Degeneration
Positive preliminary data presented for EVIZON - Breast Cancer
Positive Abraxane survival data presented - Cancer Therapy
Mean survival time doubles in patients with pancreatic cancer using RP101 - Drug Development
Aczone demonstrates reduction in number, severity of acne lesions - Drug Development
Enrollment of new patients in trials of alagebrium temporarily suspended - Hepatitis C Virus
U.S. FDA approves Pegasys and Copegus as hepatitis C treatment for HIV patients - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
